Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting Wnt5A and SRC1 in prostate cancer with siRNA

ABSTRACT: We investigated the role of Wnt5A and SRC1 in castration-resistant prostate cancer cells using corresponding siRNA.

ORGANISM(S): Homo sapiens

PROVIDER: GSE147220 | GEO | 2025/03/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Targeting Wnt5A and SRC1 in prostate cancer with siRNA

Project description:Targeting Wnt5A and SRC1 in prostate cancer with siRNA

| PRJNA613449 | ENA

Targeting AR in prostate cancer with siRNA

Project description:We investigated the role of AR in castration-resistant prostate cancer cells using AR siRNA.

2025-03-15 | GSE147219 | GEO

Targeting GATA2 in prostate cancer with siRNA

Project description:We investigated the role of GATA2 in castration-resistant prostate cancer cells using GATA2 siRNA.

2025-03-15 | GSE147217 | GEO

Human prostate cancer cells (VCaP and AIVCaP): siAR alone (single siRNA) vs. siAR plus OPRK1 (combo-siRNA)

Project description:Through comparative genomics using PDX models of androgen-dependent (AD) and castration-resistant (CR) tumors, we identify opioid receptor kappa 1 (OPRK1) as being associated with castration-resistance. Loss of OPRK1 function delays castration-resistance and inhibits castration-resistant growth of prostate cancer cells in culture and in vivo, suggesting OPRK1 as a therapeutic target. To gain insight with regard to biological function of OPRK1 under androgen-depleted condition, we set up two distinct comparisons using VCaP and AIVCaP cells. AIVCaP is an androgen-independent subline of VCaP which we established. VCaP or AIVCaP were treated with siRNA for AR plus siRNA for OPRK1 (combo-siRNA) or siRNA for AR alone (single siRNA) (n = 4 each), and then expression profile gained from microarray analysis of the respective cell line treated with combo-siRNA was compared with that of cells treated with single siRNA.

2022-04-03 | GSE194248 | GEO

Prostate cancer cell lines: non-targeting siRNA versus SChLAP1-siRNA treated

2013-07-20 | GSE40383 | GEO

Prostate cancer cell lines: non-targeting siRNA versus SChLAP1-siRNA treated

Project description:SChLAP1 is a novel long non-coding RNA expressed in prostate cancer. Here we performed transcriptional profiling of the prostate cancer cell lines LNCaP and 22Rv1 comparing non-targeting siRNA treatment versus SChLAP1-siRNA treatment. Goal was to determine the effect of SChLAP1 knockdown on gene expression in prostate cancer. Two-condition experiment: non-targeting siRNA versus SChLAP1 siRNA treated cells. Biological replicates: 1 control replicate, 2 treatment replicates. Technical replicates: 3 replicates per SChLAP1 siRNA. Cell lines: 22Rv1 and LNCaP.

2013-07-20 | E-GEOD-40383 | biostudies-arrayexpress

Targeting GATA2 in prostate cancer with siRNA

Project description:Targeting GATA2 in prostate cancer with siRNA

| PRJNA613445 | ENA

Targeting AR in prostate cancer with siRNA

Project description:Targeting AR in prostate cancer with siRNA

| PRJNA613444 | ENA

Transcription profiling by array of castration-resistant prostate cancer PC-3 cells treated with Hsp27-siRNA or control siRNA to study the role of Heat shock protein (Hsp) 27 in splicing

Project description:In order to investigate the involvement of Hsp27 in splicing, we performed a whole-genome exonic expression profiling of the castration-resistant prostate cancer PC-3 cells treated by Hsp27-siRNA or CTL-siRNA (both in biological duplicates).

2015-06-30 | E-MTAB-1786 | biostudies-arrayexpress

Targeting the MLL complex in castration-resistant prostate cancer [expression]

Project description:Resistance to androgen deprivation therapies and increased androgen receptor (AR) activity are major drivers of castration-resistant prostate cancer (CRPC). Prior work has focused on targeting AR directly; however, the identification and targeting of co-activators of AR signaling remains an underexplored area. Here we demonstrate that the MLL (mixed-lineage leukemia) complex, a well-known contributor in MLL-fusion-positive leukemia, acts as a co-activator of AR signaling. AR interacts with the MLL complex via its subunit, menin. Small molecule inhibition of the menin-MLL interaction blocks AR signaling and inhibits tumor growth in vivo. Furthermore, we find that menin is up-regulated in CRPC and high expression correlates with poor overall survival. Our study identifies the MLL complex as a co-activator of AR that can be targeted in advanced prostate cancer. ASH2L / Menin / MLL1 were knocked down using shRNA /siRNA in two prostate cancer cell lines, VCaP and LNCaP.

2015-03-02 | E-GEOD-60836 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data